drugset / Trial / NCT05891249

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

NCT05891249

Phase 4 Active not recruiting 85 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India

Timeline

Start
2023-06-05
Primary completion
2028-12-16
Completion
2028-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic

Indications